Sunday, April 19, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Trends

The Omicron Narrative

Daily Remedy by Daily Remedy
December 7, 2021
in Trends
0
The Omicron Narrative 2021.12.7

Fear is a curious emotion. It responds to the known as much as the unknown. No other emotion is like that.

Fear based narratives often pit the unknown against the known to drive a story line of changing uncertainty. This is the Omicron narrative. And we have seen it before, at the onset of the pandemic and the rise in variants of concern, particularly the delta variant. Yet we continue to follow this familiar storyline, reacting in the same patterns.

“All the world’s a stage; And all the men and women merely players;” quipped Jacques, a character in Shakespeare’s play, ‘As You Like It’, who observed that people pass through multiples phases in life – not unlike the phases of uncertainty seen whenever we receive new pandemic-related information.

First we react in fear, projecting worst case scenarios. Then we moderate against that initial fear, using data to rationalize against it. Then we react to the unknown in the initial data, projecting further fears – only to then rationalize again with additional data.

The dance is dialectic, a reverberation of outwardly projecting fears moderated by rationalizing against the fears, balancing what is known with the unknown as what is known changes over time.

We first heard of Omicron a few weeks ago, first through speculative headlines rife with curt quotations crafted to elicit fears.

“I just don’t know, because we need to wait for the data”, said Stéphane Bancel, CEO of Moderna. “But all the scientists I’ve talked to [say], ‘this is not going to be good.’”

“A new, highly contagious variant could have terrible consequences”, wrote Rachel Gutman of the Atlantic.

Nobody hears the ‘wait for the data’ or the ‘could have’. We simplify the context to the most provocative phrases. So we only hear, ‘this is not going to be good’ and ‘terrible consequences’. And we react in fear.

We react to the announcement by the World Health Organization (WHO) declaring Omicron a variant of concern. We react to the spread of the variant from country to country and then from state to state as though the variant is a horror movie villain, moving from victim to victim.

The stock market falls. Physician leaders pontificate. Politicians posture to the designated talking points. We implement travel restrictions and mask mandates. We obsess over testing, vaccinating, and vaccine efficacy. We grow more fearful and anxious. We look for someone or something to blame.

Eventually we look at the data.

We know the genetic sequence. We know there are over 30 mutations in the gene that codes for the spike protein, which affects the spread and virulence of COVID-19. But we are unsure whether these mutations are significant.

We do not know if Omicron spreads faster, evades acquired or natural immune responses, or produces more significant symptoms than other variants.

The preliminary data is promising. Among the existing cases that we know of, those who present with the Omicron variant have mild symptoms. But holding true to the narrative, we react to what is unknown, the changing uncertainty.

“Experts hope – but can’t say – Omicron causes milder cases of Covid”, was the headline from a recent newsletter in Axios. Again, nobody focuses on ‘hope’. We only focus on the ‘can’t say’, the changing uncertainty. And another round of fear reverberates.

Some decry Omicron as a conspiracy to increase vaccinations, among the unvaccinated and those eligible for boosters. Some uphold Omicron as evidence of vaccine inequities and healthcare disparities revealed over the pandemic.

As we learn more about Omicron in the coming days, we will have a better sense of what to expect. Whether Omicron proves to prolong the pandemic or to be a natural, endemic variation of a virus that naturally mutates remains to be seen – remains an unknown.

What is known is how the narrative will play out, and how the players will play their role, each reacting to the changing uncertainty through a balance of fear and data. The same dialectic, playing over and over and producing familiar patterns of behavior, from the initial responses to the subsequent reactions of changing knowns and unknowns.

The most important lesson we must learn from all of this is that the narrative determines people’s response to public health and medical information. If we want to learn from mistakes made during the pandemic – and be better prepared for future pandemics – then we should begin by changing the narrative – away from the fear based narrative of changing uncertainty to one of scientific rigor, caution, and prudence.

This may be asking too much of us. But like any narrative, the greater the challenges overcome by the protagonists, the greater the ending.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

summary

An in-depth exploration of drug pricing, including key databases like NADAC, WAC, and ASP, and how they influence the pharmaceutical supply chain, policy, and patient advocacy. The episode also introduces MedPricer's innovative pricing intelligence platform, offering valuable insights for healthcare professionals, policymakers, and patients.

Chapters

00:00 Understanding Drug Pricing Dynamics
03:52 Exploring the Drug Pricing Database
10:07 Patient Advocacy and Drug Pricing
13:56 Market Intelligence in Drug Pricing
How NADAC, WAC, and ASP Shape Drug CostsDaily Remedy
YouTube Video X-Tfwy7XKEg
Subscribe

Policy Shift in Peptide Regulation

Clinical Reads

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

by Daily Remedy
April 19, 2026
0

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • Strategies for Transitioning Off GLP-1 Injections

    Strategies for Transitioning Off GLP-1 Injections

    1 shares
    Share 0 Tweet 0
  • The Ecology of Expectation

    0 shares
    Share 0 Tweet 0
  • The First FBI Agent I Met

    2 shares
    Share 0 Tweet 0
  • The Gut Healthy Diet

    1 shares
    Share 0 Tweet 0
  • They Rarely Ask for Pain Pills Now

    1 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy